Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMHXMYU)

Drug Name	LY3361237 DMHXMYU
Drug Type	Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Systemic lupus erythematosus	DISI1SZ7	4A40.0	Phase 2	[1]
Sjogren syndrome	DISUBX7H	4A43.20	Phase 2	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05123586) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT05781451) A Phase 2, Open Label Study of Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome. U.S.National Institutes of Health.